AVENTIS US PAT DEPT AUG. 4.2005 4:43PM TO: US CENTRALIZED USPTO

CENTRAL FAX CENTER

NO. 7297

AUG 0 4 2005

PTO/SB/21 (09-04) Approved for use through 67/31/2009, OMB 0851-0031 U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Panetwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number Application Number 10/608,424 TRANSMITTAL Filing Date June 26, 2003 First Named Inventor FORM Florence BORDON-PALLIER et al. Art Unit Examiner Name BERCH, Mark L. (to be used for all correspondence after initial filing) Attorney Docket Number 2541 US CNT Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences 7 Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Provisional Application Proprietary Information Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name AVENTIS PHARMACEUTICALS INC. Signature Printed name iryigg Newman Date Reg. No. August 04, 2005 22,638 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300 _; Total No. of Pages Transmitted: 8 Signature Date Typed or printed name **Brian Pritchett** August 04, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Response dated August 4, 2005 Reply to Office action mailed May 6, 2005

RECEIVED **CENTRAL FAX CENTER** AUG 0 4 2005

NO. 7297 P. 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:

Berch, Mark L.

In re Application of

F. Bordon-Pallier, et al

Art Unit:

1624

Application No.:

10/606,424

Filed:

June 26, 2003

I hereby certify that this correspondence is being transmitted by facsimile to the Commissioner of Putents, P.O. Box 1450, Alexandria, VA 22313-1450, 571-273-8300, at

Title:

Novel Purine Derivatives, Preparation

Method and Use as Medicines

August 4, 2005
Date of Transmission

Printed Name of Person Signing:

Brian Pritchett Signature

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RESPONSE UNDER 37 C.F.R. §1.111

Sir:

In response to the Office Action mailed May 6, 2005, please consider the amendment and arguments presented for the above-captioned application as follows:

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Amendments to the Abstract A substitute Abstract appears on page 6 of this paper.

Remarks/Arguments begin on page 7 of this paper.